References
1. Letter No. 01/8458-0-32 of the Federal Service for Supervision of Consumer Protection and Human Welfare dated June 7, 2010 «About anthrax cattle trucks». (in Russian)
2. About the anthrax situation and prevention measures. July 10, 2020. URL: http://70.rospotrebnadzor.ru/epidemiologic_situation/144415/ (in Russian)
3. About anthrax in China. July 10, 2020. URL: https://www.rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=9991&sphrase_id=2572722 (in Russian)
4. Cieslak T.J., Eitzen E.M. Jr. Clinical and epidemiologic principles of anthrax. Emerg. Infect. Dis. 1999; 5 (4): 552–5.
5. Rubinshteyn E. Bioterrorism: the importance of antimicrobial drugs. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2001; 4 (3): 290–300. (in Russian)
6. Hughes J.M., Gerberding J.L. Anthrax bioterrorism: lessons learned and future directions. Emerg. Infect. Dis. 2002; 8 (10): 1013–14.
7. Belova E.V., Kolesnikov A.V., Zakharova M.Y., Dubiley S.A., Dyatlov I.A., Shemyakin I.G. Special features of immune response to the lethal toxin of bacillus anthracis. Bioorganicheskaya khimiya. 2008; 34 (5): 571–7. (in Russian)
8. Zakharova M.Y., Kuznetsov N.A., Dubiley S.A., Kozyr A.V., Fedorova O.S., Chudakov D.M., Kolesnikov A.V. Substrate recognition of anthrax lethal factor examined by combinatorial and pre-steady-state kinetic approaches. J Biol Chem. 2009; 284 (27): 17902–13.
9. Smith H. Discovery of the anthrax toxin: the beginning of in vivo studies on pathogenic bacteria. Trends Microbiol. 2000; 8 (5): 199–200.
10. Aulinger B.A., Roehrl M.H., Mekalanos J.J., Collier R.J., Wang J.Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect. Immun. 2005; 73 (6): 3408–14.
11. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature. 1997; 385 (6619): 833–8.
12. Green B.D., Flatt P.R., Bailey C.J. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc. Dis. Res. 2006; 3 (3): 159–65.
13. Little S.F., Novak J.M., Lowe J.R., Leppla S.H., Singh Y., Klimpel K.R., Friedlander A.M. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology. 1996; 142 (3): 707–15.
14. Liu S., Zhang Y., Hoover B., Leppla S.H. The receptors that mediate the direct lethality of anthrax toxin. Toxins (Basel). 2012; 5 (1): 1–8.
15. Kirby J.E. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. 2004; 72 (1): 430–9.
16. Comer J.E., Chopra A.K., Peterson J.W., König R. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect. Immun. 2005; 73 (12): 8275–81.
17. Kelly-Cirino C.D., Mantis N.J. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect. Immun. 2009; 77 (11): 4859–67.
18. Brossier F., Lévy M., Landier A., Lafaye P., Mock M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect. Immun. 2004; 72 (11): 6313–7.
19. Little S.F., Leppla S.H., Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 1988; 56 (7): 1807–13.
20. Mohamed N., Clagett M., Li J., Jones S., Pincus S., D’alia G., Nardone L., Babin M., Spitalny G., Casey L. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 2005; 73 (2): 795–802.
21. Mazumdar S. Raxibacumab. MAbs. 2009; 1 (6): 531–8.
22. Albrecht M.T., Li H., Williamson D., LeButt C.S., Flick-Smith H.C., Quinn C.P., et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect. Immun. 2007; 75 (11): 5425–33.
23. Peterson J.W., Comer J.E., Noffsinger D.M., Wenglikowski A., Walberg K.G., Chatuev B.M. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect. Immun. 2006; 74 (2): 1016–24.
24. Hou A.W., Morrill A.M. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection. Ann. Pharmacother. 2017; 51 (10): 908–13.
25. Maynard J.A., Maassen C.B.M., Leppla S.H., Brasky K., Patterson J.L., Iverson B.L. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 2002; 20 (6): 597–601.
26. Mabry R., Rani M., Geiger R., Hubbard G.B., Carrion R. Jr, Brasky K. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect. Immun. 2005; 73 (12): 8362–8.
27. Greig S.L. Obiltoxaximab: first global approval. Drugs. 2016; 76 (7): 823–30.